Geneyx provides comprehensive next-generation sequencing data analysis. The company's AI-based platform combines diverse databases to streamline the diagnostics process. Its platform also enables patients and physicians to access a variety of clinical data sets. In addition, it provides access to a wide variety of knowledge-based genomic interpretation and reports. The platform also helps patients and physicians understand the genetic variations responsible for certain diseases. These capabilities have a direct impact on patient care and health outcomes.
As next-generation sequencing becomes a more common diagnostic tool, the challenge of integrating genomic data with real-time clinical evidence has become increasingly complex. This problem has led to siloed analysis and interpretation of genetic data in research institutions and hospitals around the world. The silosism of these data and the lack of standardization in the way these data are analyzed hampers the development of more effective therapies. Geneyx addresses this challenge by providing clinical and diagnostic support for the analysis and interpretation of genetic data.
Accenture recently announced its strategic investment in Israel-based startup Geneyx Genomex Ltd., which develops genomic analysis software. The company's AI-based analysis platform harnesses genetic data to guide digital insights. Geneyx plans to use its new funding to accelerate global growth and achieve its goal of 90 percent diagnostic yield in two years. By partnering with Accenture Ventures, Geneyx is now part of Accenture Ventures Project Spotlight.
Accenture Ventures is a leading investment firm in the biotechnology industry. The company's INTIENT platform connects deeper intelligence with actions, and helps clients achieve their goals. Through an open partner ecosystem and a leading cloud platform, Accenture helps life science companies advance New Science through innovation and collaboration. The company's INTIENT platform enables scientists to connect human creativity with technology. A comprehensive data management platform also helps companies improve collaboration among scientists.
Using genetic data analysis and interpretation, Geneyx aims to improve access to preventative healthcare. It provides tools for genomic data analysis that identify hereditary illnesses before they manifest. These results make preventative healthcare easier. Sadly, many hereditary diseases aren't discovered until it's too late to treat them. But thanks to advances in technology, genetic testing has made this process a reality for patients. For example, genetic analysis can help physicians predict cancer earlier.
Investing in genetics stocks can be risky due to volatility and regulatory approval. Many investors seek exposure to the industry by purchasing exchange-traded funds (ETFs). However, these mutual funds are less volatile than single stocks. Some of the largest genetics companies include Amgen, BioNTech, and Vertex Pharmaceuticals. Once an investor decides to purchase an ETF, they will have a clearer picture of which companies are most promising.